key: cord-0267440-fhccwxku
authors: Ainslie, K. E. C.; Riley, S.
title: Is annual vaccination best? A modelling study of influenza vaccination strategies in children
date: 2021-09-26
journal: nan
DOI: 10.1101/2021.09.22.21263935
sha: a3c4359440253e6e14398fc2533d27f3f778b2ef
doc_id: 267440
cord_uid: fhccwxku

Introduction: Annual vaccination of children against influenza is a key component of vaccination programs in many countries. However, past infection and vaccination may affect an individual's susceptibility to infection. Little research has evaluated whether annual vaccination is the best strategy. Using the United Kingdom as our motivating example, we assess the impact of different childhood vaccination strategies, specifically annual and biennial (every other year), on attack rate and expected number of infections. Methods and Findings: We present a multi-annual, individual-based, stochastic, force of infection model that accounts for individual exposure histories and disease/vaccine dynamics influencing susceptibility. We simulate birth cohorts that experience yearly influenza epidemics and follow them until age 18 to determine attack rates and the number of childhood infections. We perform simulations under baseline conditions, with an assumed vaccination coverage of 44%, to compare annual vaccination to no and biennial vaccination. We relax our baseline assumptions to explore how our model assumptions impact vaccination program performance. At baseline, we observed more than a 50% reduction in the number of infections between the ages 2 and 10 under annual vaccination in children who had been vaccinated at least half the time compared to no vaccination. When averaged over all ages 0-18, the number of infections under annual vaccination was 2.07 (2.06, 2.08) compared to 2.63 (2.62, 2.64) under no vaccination, and 2.38 (2.37, 2.40) under biennial vaccination. When we introduced a penalty for repeated exposures, we observed a decrease in the difference in infections between the vaccination strategies. Specifically, the difference in childhood infections under biennial compared to annual vaccination decreased from 0.31 to 0.04 as exposure penalty increased. Conclusion: Our results indicate that while annual vaccination averts more childhood infections than biennial vaccination, this difference is small. Our work confirms the value of annual vaccination in children, even with modest vaccination coverage, but also shows that similar benefits of vaccination can be obtained by implementing a biennial vaccination program.

Influenza is a significant cause of morbidity and mortality annually [1] , which is likely to 2 cause substantial waves of infection as COVID-19 social distancing is relaxed. 3 Pre-COVID-19, 20% to 30% of children were infected with influenza compared to only 4 5% to 10% of adults, annually [2] . The World Health Organization lists children under 5 the age of 5 years old as a target group for influenza vaccination [3] because more than 6 100,000 children under five die of influenza each year, and attack rates in children are 7 four-to five-fold higher in children compared to adults [2] . Additionally, influenza 8 infection in children can lead to complications and severe disease with the highest 9 incidence of influenza-related hospitalisations in young children [4] . Due to the disease 10 burden of influenza, the United Kingdom began offering the influenza vaccine to all 11 primary school aged children (those aged 6-10 years) in England in the winter of 12 2019/2020 for the first time [5] . This group was also targeted because school-aged 13 children are thought to drive influenza transmission [6] . Prior modelling work has 14 shown that adopting a transmission-based approach to vaccination can reduce the 15 spread of influenza by targeting groups that drive transmission (such as children) [7] . 16 Modelling is an important tool that can aid policy decisions surrounding vaccination 17 programs by exploring the impacts of different strategies and scenarios [8] . Unlike other 18 childhood vaccines, the influenza vaccine must be re-administered each year due to 19 continuous changes in the virus [9, 10] ; therefore decisions to implement a recurring 20 influenza vaccination policy must be weighed against other considerations, such as 21 economic cost. Many prior modelling studies have focused on quantifying the impacts of 22 childhood vaccination programs [8, [11] [12] [13] [14] [15] [16] , including studies that have specifically 23 assessed the impact of childhood vaccination programs in England [7, 12, 13] . 24 Overwhelmingly, these studies have found both direct and indirect benefits of childhood 25 vaccination programs. Additionally, studies have found that prevention of influenza 26 infection and subsequent disease by vaccination is a cost-effective method of preventing 27 influenza [17, 18] . While the specific assumptions and models vary across these studies, 28 they all focus on annual vaccination programs and do not account for the potential 29 negative effects of repeated exposures. 30 It is still unclear whether repeated influenza vaccination results in negative effects whereby individuals who receive multiple vaccines over a short period of time have 32 increased risk of infection compared to individuals who received a vaccine only in the 33 current season. The first report of the potential negative effects of repeated annual 34 vaccination was published in a series of papers describing influenza outbreaks at a 35 British boarding school from 1972 to 1976 [19] [20] [21] . Repeated influenza vaccination has 36 received growing interest [22] and observational and modelling studies have shown that 37 repeated annual vaccination may result in less protection against influenza 38 infection [21, [23] [24] [25] [26] [27] [28] . This phenomenon may be due to an individual's immune system 39 generating the strongest response to their first exposure and then less strong responses 40 to subsequent exposures of a similar type [29] . Alternatively, the increased risk of 41 infection after repeated vaccination could be due to negative interference from closely 42 related vaccine strains such that the response to the second vaccine strain is partially 43 eliminated by pre-existing cross-reactive antibodies produced in response to the first 44 vaccine strain [23] . The precise mechanism whereby reduced protection after repeated 45 vaccination remains unclear. 46 Here, we assessed how different frequencies of vaccination may impact childhood 47 infections while also accounting for potential negative impacts of repeated exposures. match, and waning. This work could have impact on future policy surrounding repeated 53 vaccination programs, but the focus of this paper is not on changing policy, but rather 54 on quantifying potential benefits of 1) current annual vaccination strategies in children 55 and 2) alternative strategies for those countries where annual vaccination programs are 56 not feasible. We use the vaccination program in the UK as our motivating example. We 57 first assess annual vaccination programs in young and school-aged children (aged 2-10 58 years) compared to no vaccination program. We next assess the benefits of a biennial 59 (every other year) vaccination program compared to an annual program. We quantify 60 the performance of each vaccination program over many seasons as the expected [36] . However, they are only updated when there has been 83 significant evolution of the viral strains [37] . The cumulative antigenic distance 84 since the last vaccine update determines when the next vaccine update will occur. 85 When the cumulative sum of the antigenic distance since the last vaccine update 86 reaches a threshold (for example, 3 antigenic units) the vaccine is updated 87 (Fig 1A) . year and used to inform their susceptibility in subsequent years.

(a) We assume a leaky vaccine model [38] . In other words, we assume that 107 everyone who receives a vaccine is partially protected from infection.

(b) Immunity from vaccination is assumed to wane a fixed percentage each year, 109 although there is some evidence that live-attenuated influenza vaccines may 110 provide protection for longer [39] . Waning is modelled as a separate term, so 111 that it is distinct from antigenic drift of the circulating strain away from the 112 vaccine strain. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 26, 2021. ;  UK vaccination policy is to annually vaccinate children aged 2 to 10 years [5] . Thus, we 178 implemented the following vaccination strategies in children: 1) no vaccination; 2) 179 annual vaccination from ages 2 to 10; 3) biennial (every other year) vaccination from 180 ages 2 to 10. We also perform a sensitivity analysis in which vaccination occurs from 181 ages 2 to 16.

Within each simulation we identified birth cohorts beginning in 2000 until 2010, and 183 followed each cohort until the cohort members reached age 18. We varied our model Table 1 ). At ages with the lowest rates of infection, annual 208 attack rates under the annual vaccination strategy were 2-fold lower compared to the 209 no-vaccination strategy (Fig 2A) . However, immediately after the oldest age of 210 vaccination (11 years), we observed an increase in attack rate to a level greater than 211 that expected from the no vaccination strategy. We observed the same pattern in 212 expected number of childhood infections (Fig 2B) . Overall, no vaccination resulted in (Table 1) . However, when we look at the ages in which children get infected we 216 see that during the vaccination program (ages 2-10) there is a more pronounced 217 difference in numbers of infections between vaccination strategies. We observed more 218 than a 50% decrease in infections under an annual vaccination program for those who 219 were vaccinated at least half the time (i.e., received at least 5 vaccinations between the 220 ages of 2-10) compared to no vaccination strategy (Fig 2, Table 1 ).

The benefit from repeated annual vaccination was sensitive to our assumption about 222 the immunological exposure penalty. To better understand the effect of exposure 223 penalty, we plotted the attack rates (Fig 3) and determined the number of childhood 224 infections (Table 1) for different values of exposure penalty under the baseline scenario. 225 For plausible values of the exposure penalty, we observed substantial reductions in the 226 benefits of repeated annual vaccination. We found that the benefit of annual vaccination 227 September 22, 2021 6/23

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 26, 2021. ;  decreased as exposure penalty increased, specifically, we saw an increase in attack rate 228 in later years of childhood as the number of vaccinations individuals received increased 229 (Fig 3) 2.63, 2.65) , respectively). Our results were robust to the value of force of 235 infection when we allowed force of infection to vary by year (Fig. S3, Table S1 ). 236 Next, we used the model to compare repeated annual vaccination and repeated 237 biennial vaccination with respect to attack rates and expected number of infections up 238 to the age of 18 (Fig 2, Table 1 ). At ages in which the vaccine was offered in both 239 vaccination strategies, annual vaccination resulted in lower or similar attack rates 240 compared to biennial vaccination under our baseline scenario (Fig 2A) . For ages in 241 which the vaccine was not offered under the biennial strategy, attack rates increased to 242 similar or higher rates as that expected from the no vaccination strategy. Additionally, 243 as we saw under the annual vaccination strategy, the attack rates under the biennial 244 strategy increased after the oldest age of vaccination (age 11 As we observed with annual vaccination, the benefit of repeated biennial vaccination 252 was sensitive to our assumption about the immunological exposure penalty. We found 253 that as exposure penalty increased, the benefit of biennial vaccination decreased (Fig 3) . 254 Attack rates increased in later years of childhood under biennial vaccination (in ages in 255 which the vaccine was offered); however, they increased more slowly than under annual 256 vaccination, resulting in lower attack rates under biennial vaccination compared to (Fig 4B) . We found that the largest absolute differences occurred for high 287 values of vaccine effectiveness, and that annual vaccination resulted in fewer infections 288 than biennial vaccination. However, when vaccine effectiveness was low, there were only 289 small differences in the number of childhood infections resulting from the two 290 vaccination strategies. To assess how each model parameter impacted the difference in 291 childhood infections, we created bivariate scatter plots for each combination of model 292 parameters (Fig. S1 ). We found that vaccine effectiveness and exposure penalty were 293 the strongest determinants of vaccine strategy performance.

Current UK policy is to vaccinate children aged 2 to 10 years for influenza [5] ; 295 however that policy is expected to be extended to children aged 11 to 16 years [46] . we found that annual vaccination mostly outperformed biennial vaccination (Fig. S2) . 305 There was no clear pattern of model parameters in which biennial vaccination 306 outperformed annual vaccination; however, there were more parameter combinations for 307 which biennial outperformed annual (green dots). These parameter combinations all 308 featured an exposure penalty greater than 0 and many also corresponded to a high 309 vaccine effectiveness (Fig. S2A) .

Our work confirms the value of annual influenza vaccination in children by considering 312 the average number of infections per participant during their childhood. We found that 313 an annual influenza vaccination program reduced childhood infections compared to no 314 vaccination program. Differences in childhood infections were most pronounced during 315 the years in which children received the vaccine (ages 2-10). We observed a 2-fold 316 reduction in childhood infections from ages 2-10 under an annual vaccination program 317 in children who were vaccinated at least half the time compared to no vaccination. Due 318 to our baseline assumptions that the vaccine-induced immunity waned completely after 319 one year and vaccine coverage was 44% [43] , averaging over all ages diluted differences 320 in expected numbers of infections. Regardless, the reduction of infections under an 321 annual vaccination program were robust to different model assumptions and support 322 current childhood influenza vaccination programs in several countries [5, 32, 47, 48] . 323 We also considered a biennial vaccination program in which children are vaccinated 324 every other year. We found that while annual vaccination averts more childhood While this study provides a framework by which to assess different frequencies of 355 vaccination, it is a theoretical modelling study. Due to the unavailability of longitudinal 356 data of repeated exposures in birth cohorts, this model has not been fit to data; 357 however, the parameter values used in this study are informed by the literature.

Longitudinal data of birth cohorts which track infection and vaccination history are not 359 routinely collected. In 2019 the National Institutes of Health funded two birth cohort 360 studies to evaluate the immune response to children's first exposures to influenza [50] . 361 Once data from these and similar studies is made available, this model can be adapted 362 to fit to data. The approach taken here for children may be appropriate for studies of COVID-19 374 vaccination in all ages. As more data accumulate on the duration of protection from 375 severe disease and the impact of evolutionary change, many countries may choose to opt 376 for repeated vaccine boosters based on update target lineages. Should this occur, the 377 same trade-offs will likely apply as have been demonstrated here. Crucially, longitudinal 378 studies should be started as soon as possible so that the impact of repeated vaccination 379 can be estimated. 380 We make several simplifying assumptions in this work. Specifically, we do not 381 September 22, 2021 9/23 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 26, 2021. ;  stratify our population by risk factor. Thus, we assume that the risk of infection is 382 determined by prior exposure only and not an underlying condition. We don't expect 383 this simplification to impact our results. We also assume that vaccine effectiveness is 384 the same for all individuals regardless of age. There is evidence that suggests that 385 vaccines may be less effective in the elderly [51] . However, the focus of this modelling 386 study is on children and thus, the assumed vaccine effectiveness in other age groups will 387 not impact the results presented here. Additionally, vaccine characteristics such as 388 waning immunity are unlikely to vary among the similarly aged individuals who are the 389 focus group of this work. Therefore, we assume a fixed waning rate. Finally, we consider 390 a model with only one circulating virus strain, thus we do not incorporate 391 cross-reactivity of similar strains into our susceptibility model. A similar approach has 392 been taken in other modelling studies [8, 16, 49] .

In conclusion, we developed a model to assess the potential benefits of long-term . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 26, 2021. ; https://doi.org/10.1101/2021.09.22.21263935 doi: medRxiv preprint

Estimates of global seasonal influenza-associated respiratory mortality: a modelling study

European Scientific Working Group on Influenza. Bringing childhood flu vaccination to the next level: report and roadmap to actions

Incidence of influenza-related hospitalizations in different age groups of children in Finland: a 16-year study

Annual National Flu programme letter

On the relative role of different age groups in influenza epidemics

Assessing Optimal Target Populations for Influenza Vaccination Programmes: An Evidence Synthesis and Modelling Study

Vaccinating children against influenza increases variability in epidemic size

The evolution of human influenza viruses

Burden, effectiveness and safety of influenza vaccines in elderly, paediatric and pregnant populations

Population-wide benefits of routine vaccination of children against influenza

Estimating the impact of childhood influenza vaccination programmes in England and Wales

Estimating the clinical impact of introducing paediatric influenza vaccination in England and Wales

The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study

Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model. Appl Health Econ Health Policy

The impact of influenza vaccination on infection, hospitalisation and mortality in the Netherlands between

Cost-effectiveness and socio-economic aspects of childhood influenza vaccination

Economic evidence of influenza vaccination in children

Controlled trial of inactivated influenza vaccine containing the a-Hong Kong strain during an outbreak of influenza due to the a-England-42-72 strain

Influenza at Christ's Hospital: March

Assessment of inactivated influenza A vaccine after three outbreaks of influenza A at Christ's Hospital

The impact of repeated vaccination on influenza vaccine effectiveness: a systematic review and meta-analysis

Variable efficacy of repeated annual influenza vaccination

Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies

Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period

Repeat Influenza Vaccination and High-Dose Efficacy

Influenza vaccination and risk of hospitalization among adults with laboratory confirmed influenza illness

Negative effect on immune response of repeated influenza vaccination and waning effectiveness in interseason for elderly people

On the Doctrine of Original Antigenic Sin

Epidemiology and pathogenesis of influenza

Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Seasonal influenza vaccination and antiviral use in EU/EEA Member States. European Centre for Disease Prevention and Control

Epochal Evolution Shapes the Phylodynamics of Interpandemic Influenza A (H3N2) in Humans

Strength and tempo of selection revealed in viral gene genealogies

Influenza vaccine: the challenge of antigenic drift

Selection of influenza vaccine strains and developing pandemic vaccines

Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies

Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia

Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model

Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulation virus and the effect of prior vaccination on estimates

Quantifying the transmissibility of human influenza and its seasonal variation in temperate regions

Immunisation and Countermeasures, National Infection Service. Seasonal influenza vaccine uptake in GP patients: winter season

A Comparison of Three Methods for Selecting Values of Input Variables in the Analysis of Output from a Computer Code

R: A language and environment for statistical computing

Joint Committee on Vaccination and Immunisation. Minute of the meeting held on Friday

Cost-effectiveness of influenza vaccination of healthy children

Vaccine recommendations for children and youth for the 2020/2021 influenza season

Vaccinating children against influenza: overall cost-effective with potential for undesirable outcomes

Long-term studies will track indelible marks of first flu

Antibody response to influenza vaccination in the elderly: a quantitative review

Health and economic impact of the seasonal influenza vaccination programme in England